March 28, 2024: MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview
MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview The DSMB, based on Phase 3 trial ARES preliminary data, concluded that MaaT013 has a favorable benefit/risk ratio with “high efficacy and low toxicity” in 3rd line aGvHD[1]. This evaluation confirms previous ones in a similar patient population from the EAP[2]. Primary endpoint ORR [...] 